Royalty Pharma's Exceptional 2024 Performance and 2025 Outlook
Royalty Pharma's Financial Performance and Growth in 2024 Royalty Pharma plc (Nasdaq: RPRX) has showcased an impressive growth trajectory, with Portfolio Receipts reaching $742 million in the fourth quarter of 2024, contributing to a total of $2,801 million for the fiscal year 2024. This growth can be attributed to a 12% increase in Royalty Receipts for Q4 and 13% for the...
Continue Reading